LYTIX BIOPHARMA ASA: årsregnskap 2012 vs 2011
Shrank 6% on revenue, cash halved-plus
Summary
What changed
Comparing Årsregnskap 2012 with 2011 for LYTIX BIOPHARMA ASA. Revenue 53.9k NOK → 50.5k NOK (-6.3%). Equity 40.33m NOK → 17.95m NOK.
On the constructive side: operating result improved. Pressures included: revenue fell; equity eroded; cash fell.
Also worth watching: sharp cash drawdown; paid-in equity reduced. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -41.66m NOK → -32.00m NOK (op. margin -77297.3% → -63365.4%). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 53.9k NOK to 50.5k NOK (-6.3% YoY). Calculated
-
↓
Equity eroded
Book equity 40.33m NOK → 17.95m NOK (equity ratio 78.3% → 72.3%). Calculated
-
↓
Cash fell
Bank deposits 43.45m NOK → 8.44m NOK (-80.6% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (43.45m NOK → 8.44m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 40.33m NOK → 17.95m NOK — check capital reduction, conversion, or reclassification. Interpretation